Trends and predictive factors for treatment failure following artemisinin-based combination therapy among children with uncomplicated malaria in Ghana: 2005–2018

Table 1 Details of data analyzed

Year of study	Test medicines	Number Enrolled	Age range	Sponsor	Status of data	Data source
2005	ASAQ: Non-fixed combination	543	6 mths–59 mths	^*GF	Published [36, 37]	9 sites
2007	ASAQ: Non-fixed combination	496	6 mths–59 mths	^*GF	Published [37]	9 sites
2010	ASAQ: Fixed combination	126	6 mths–9 yrs	^*GF	Published [37]	3 sites
	AL: Fixed combination	181	6 mths–9 yrs	^*GF	Published [37, 37]	5 sites
2012	ASAQ: Fixed combination	164	6 mths–9 yrs	⁺NAMRU-3	Unpublished	3 sites
2013	ASAQ: Fixed combination	159	6 mths–9 yrs	^*GF	Published [39]	4 sites
	AL: Fixed combination	171	6 mths–9 yrs	^*GF	Published [39]	3 sites
2014	ASAQ: Non-fixed combination	191	6 mths–14 yrs	⁺NIH	Published [16]	2 sites
2015	ASAQ: Fixed combination	492	6 mths–9 yrs	^*GF	Published [13]	9 sites
	ASAQ: Non-fixed combination	237	6 mths–14 yrs	⁺NIH	Unpublished	2 sites
	AL: Fixed combination	472	6 mths–9 yrs	^*GF	Published [13]	8 sites
2016	ASAQ: Non-fixed combination	141	6 mths–14 yrs	⁺NIH	Unpublished	2 sites
2017	ASAQ: Non-fixed combination	192	6 mths–14 yrs	⁺NIH	Unpublished	2 sites
2018	ASAQ: Fixed combination	692	6 mths–9 yrs	^*GF	Unpublished	9 sites
	AL: Fixed combination	653	6 mths–9 yrs	^*GF	Unpublished	10 sites

ASAQ Artesunate-Amodiaquine combination, AL Artemether-Lumefantrine combination, GF Global Fund, NAMRU-3: Naval Medical Research unit 3, NIH National Institute of Health; *Routine surveillance years with 2–3 years interval; ⁺Part of in-vitro/ex-vivo studies

ISSN: 1471-2334